Get the Stockscreener App
24.75
1.73%
0.42
After Hours:
24.76
0.01
+0.04%
Ideaya Biosciences Inc stock is traded at $24.75, with a volume of 1.09M.
It is up +1.73% in the last 24 hours and up +14.64% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$24.33
Open:
$24.35
24h Volume:
1.09M
Relative Volume:
0.99
Market Cap:
$2.17B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-11.30
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
+8.36%
1M Performance:
+14.64%
6M Performance:
+21.09%
1Y Performance:
-34.45%
1-Day Range:
$24.18
$25.11
1-Week Range:
$22.82
$25.11
52-Week Range:
$13.45
$40.74
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
24.75 | 2.13B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.88 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.87 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.91 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
661.32 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.32 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
IDEAYA Biosciences announces agenda for upcoming R&D day By Investing.com - Investing.com South Africa
IDEAYA Biosciences announces agenda for upcoming R&D day - Investing.com
New Clinical Data Coming: IDEAYA's 3 Cancer Drugs Show Promise in Melanoma and Lung Cancer Trials - Stock Titan
Can IDEAYA Biosciences Inc. expand into new marketsWeekly Trade Review & Real-Time Buy Zone Alerts - classian.co.kr
How to use a screener to detect IDEAYA Biosciences Inc. breakoutsBuy Strategy Tracker with Growth Indicators - Newser
Analyzing net buyer seller activity in IDEAYA Biosciences Inc.Ten-Year Sector Performance and Summary Analysis - Newser
How sentiment analysis helps forecast IDEAYA Biosciences Inc.Risk Shielded Trade Watch with Analysis - Newser
Leerink Partnrs Has Bullish Estimate for IDYA Q3 Earnings - Defense World
Has IDEAYA Biosciences Inc. found a price floorFree Entry Zone Strategy for Consistent Profit - Newser
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events - Louisiana First News
Cantor Fitzgerald Issues Negative Forecast for IDYA Earnings - Defense World
Will IDEAYA Biosciences Inc. outperform the marketLow Volatility Stock Analysis With Confidence - Newser
Is a relief rally coming for IDEAYA Biosciences Inc. holdersTen-Year Sector Performance and Summary Analysis - Newser
GSK and Ideaya’s Promising Study on Solid Tumors: A Potential Game-Changer? - TipRanks
IDEAYA Biosciences: Hold Rating Amid Key Pipeline Developments and Anticipated Clinical Milestones - TipRanks
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $48.09 Average PT from Analysts - Defense World
Wedbush Predicts Increased Earnings for IDEAYA Biosciences - Defense World
RBC Capital Remains a Buy on IDEAYA Biosciences (IDYA) - The Globe and Mail
IDEAYA Biosciences Reports Q2 2025 Financial Results - The Globe and Mail
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Ideaya Biosciences, Hengrui announce oral presentation at IASLC 2025 - MSN
Risk vs reward if holding onto IDEAYA Biosciences Inc.Free Early Breakout Entry Point Notifications - Newser
IDEAYA Biosciences Inc Reports Q2 2025 Financial Results: Net Loss of $77.5 Million, EPS of -$0.88, and No Revenue - AInvest
Ideaya Biosciences Q2 EPS Beats Consensus, Sees Catalyst-Rich Period Ahead - AInvest
GSK and Ideaya’s Promising Study on Tumor-Reducing Drug GSK4418959 - TipRanks
Chart based analysis of IDEAYA Biosciences Inc. trendsPredictive Model for Intraday Swing Forecast - Newser
Ideaya Biosciences shares rise 3.19% premarket after reporting Q2 net loss and positive trial data. - AInvest
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
IDEAYA (IDYA) Q2 Net Loss Improves 27% - The Motley Fool
IDEAYA (IDYA) Q2 Net Loss Improves 27% - Nasdaq
IDEAYA Biosciences Reports Q2 Net Loss of $0.88 - MarketScreener
IDEAYA Biosciences Enters ADC Market with Solid Tumor Focus - AInvest
IDEAYA Biosciences: Moving Into ADCs For Solid Tumors (NASDAQ:IDYA) - Seeking Alpha
Ideaya Biosciences earnings missed by $0.09, revenue topped estimates - Investing.com
IDEAYA Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
IDEAYA Biosciences Reports Q2 GAAP EPS of -$0.88, Misses Expectations - AInvest
IDEAYA Biosciences's Q2 net loss widens as costs mount - MarketScreener
IDEAYA Reports Phase 2/3 Trial Data and Neoadjuvant Darovasertib Results - AInvest
Published on: 2025-08-05 04:17:11 - metal.it
Ideaya Biosciences Advances in Ocular Melanoma Treatment with Darovasertib Study - TipRanks
Ideaya Biosciences shares rise 6.02% premarket as New Zealand shares down tracking Wall Street sell-off. - AInvest
What institutional investors are buying IDEAYA Biosciences Inc. stockCapitalize on proven trading setups - Jammu Links News
How many analysts rate IDEAYA Biosciences Inc. as a “Buy”Maximize portfolio growth with expert advice - Jammu Links News
How does IDEAYA Biosciences Inc. compare to its industry peersConsistent triple-digit returns - Jammu Links News
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - cnhinews.com
What analysts say about IDEAYA Biosciences Inc. stockGet expert advice on portfolio optimization - Jammu Links News
Should I hold or sell IDEAYA Biosciences Inc. stock in 2025Unlock powerful portfolio management tools - Jammu Links News
What makes IDEAYA Biosciences Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
What drives IDEAYA Biosciences Inc. stock priceMaximize gains with strategic stock entries - Jammu Links News
What is the risk reward ratio of investing in IDEAYA Biosciences Inc. stockGet alerts on the hottest stocks daily - Jammu Links News
How strong is IDEAYA Biosciences Inc. company’s balance sheetMarket-crushing stock picks - Jammu Links News
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):